Identifying genetic variants that affect drug response or play a role in disease is an important task for clinicians and researchers. Before individual variants can be explored efficiently for effect on drug response or disease relationships, specific candidate genes must be identified. While many methods rank candidate genes through the use of sequence features and network topology, only a few exploit the information contained in the biomedical literature. In this work, we train and test a classifier on known pharmacogenes from PharmGKB and present a classifier that predicts pharmacogenes on a genome-wide scale using only Gene Ontology annotations and simple features mined from the biomedical literature. Performance of F=0.86, AUC=0.860 is achieved. The top 10 predicted genes are analyzed. Additionally, a set of enriched pharmacogenic Gene Ontology concepts is produced.
Introduction
One of the most important problems in the genomic era is identifying variants in genes that affect response to pharmaceutical drugs. Variability in drug response poses problems for both clinicians and patients. 1 Variants in disease pathogenesis can also play a major factor in drug efficacy. 2, 3 However, before variants within genes can be examined efficiently for their effect on drug response, genes interacting with drugs or causal disease genes must be identified. Both of these tasks are open research questions.
Databases such as DrugBank 4 and The Therapeutic Target DB 5 contain information about gene-drug interactions, but only The Pharmacogenomics Knowledgebase (PharmGKB) 6 contains information about how variation in human genetics leads to variation in drug response and drug pathways. Gene-disease variants and relationships are contained in Online Mendelian Inheritance in Man (OMIM), 7 the genetic association database, 8 and the GWAS catalog. 9 Curated databases are important resources, but they all suffer from the same problem: they are incomplete. 10 One approach to this problem is the development of computational methods to aid in database curation. We explore here a method that takes advantage of the large amount of information in the biomedical literature that is waiting to be exploited.
Having a classifier that is able to predict as-yet-uncurated pharmacogenes would allow researchers to focus on identifying the variability within the genes that could affect drug response or disease, and thus, shorten the time until information about these variants is useful in a clinical setting. (We use the term "pharmacogene" to refer to any gene such that a variant has been seen to affect drug response or is implicated in a disease.) Computational methods have been developed to predict the potential relevance of a gene to a query drug. 11 Other computational methods have been developed to identify genetic causes underlying disorders through gene prioritization, but many of these are designed to work on small sets of diseasespecific genes. [12] [13] [14] [15] [16] [17] The method which is closest to the one that we present here is described in Costa et al.; 18 they create separate classifiers to predict morbidity-associated and druggable genes on a genome-wide scale. A majority of these methods use sequence-based features, network topology, and other features from curated databases; only a few use information from literature. 12, 16, 17 In the work presented here, the goal is to predict pharmacogenes at genome-wide scale using a combination of features from curated databases and features mined from the biomedical literature. We evaluate a number of hypotheses:
(1) There is a set of GO concepts that are enriched when comparing the functions of important pharmacogenes and the rest of the human genome and by examining this set of enriched GO concepts, a classifier can be created to provide hypotheses regarding further genes in which variants could be of importance. (2) Text-mined features will increase performance when combined with features from curated databases.
Methods

Pharmacogenes
By pharmacogene, we mean any gene such that a variant of that gene has been seen to affect drug response or such that variants have been implicated in disease. PharmGKB contains over 26,000 genes, with only a few having annotations that signify their importance in disease or drug response. For the experiments reported here, only those genes in which a variant exists in the PharmGKB relationship database, specifically gene-disease or gene-drug relationships, are considered to be gold-standard pharamcogenes. By this definition, 1,124 genes meet the criteria for classification as pharamcogenes and are positively labeled training instances; these make up <5% of all genes in PharmGKB. PharmGKB is constantly being updated, so a snapshot of PharmGKB on May 2, 2013 was taken and is used as the gold standard.
Background genes
The rest of the 25,110 genes in PharmGKB, which do not contain disease or drug relationships, are considered to be background genes and will be used as negatively labeled training instances. We acknowledge the fact that PharmGKB is incomplete and that a missing annotation is not indicative of a gene not being involved in disease or drug relationships, but the fact that they have not been discovered or curated yet. (This is an obvious motivation for the work reported here.) Two data sets were created from the background genes. One consists of all 25,110 genes. This is referred to as the unbalanced set. The second consists of 1,124 background genes that have similar numbers of publications as the known pharamcogenes. This is referred to as the balanced set. That is, the two sets differ in whether or not they result in a balanced set of positive and negative exemplars.
Functional annotations from curated databases
Links within PharmGKB were used to obtain Entrez Gene (EG) identifiers for both pharmacogenes and background genes. To extract all Gene Ontology (GO) 19 annotated functions associated with these genes, the NIH's gene2go file was used. Only curated evidence codes (EXP, IDA, IPI, IMP, IGI, IEP, TAS, and ISS) were used, in order to ensure high-quality annotations. This dataset will be referred to as the curated dataset. It contains many EGID to GO ID mappings obtained solely from curated GO annotations.
Functional annotations from biomedical literature
Entez Gene IDs and the NIH's gene2pubmed file were used to relate genes to documents of which they are the primary subject. By using the gene2pubmed file, we assume that all information retrieved from the article is associated with the gene that is the primary subject. Note that this is not always true and could introduce noise. The 26,234 genes are mapped to 379,978 unique PubMed/MEDLINE articles. From these ∼380,000 articles, two different textual datasets were created, one consisting only of abstracts and the other containing full text. The abstract dataset consists of all abstracts from all articles. For ∼26,000 articles, we were only able to download XML or plain text, because PMC articles are available in any format, with some, such as PDF, not being suitable for natural language processing. The ∼26,000 full-text articles constitute our full-text dataset. All full-text documents come from the PubMed Open Access Subset.
To extract gene functions (GO concepts) from these corpora, ConceptMapper, a dictionarybased concept recognizer, 20 was used with parameters tuned for each branch of the Gene Ontology (Molecular Function, Biological Process, and Cellular Component), as seen in Funk et al. (under review). Descriptive statistics of the documents and the functional annotations retrieved from them and from the curated database are shown in Table 1 . Table 1 . Summary of gene-document and gene-annotation associations The number of genes within each dataset along with the mean number of biomedical literature documents associated with each set of genes and mean number of GO annotations per gene. (+) denotes that this set of genes is the positive labeled set while (-) denotes the negative training sets. The row labelled "Total Numbers" gives the count, not means, of documents and GO annotations. By default LibSVM maximizes accuracy; with the unbalanced dataset, this is not optimal, so weights of 90.0 and 10.0 were assigned to the pharmacogene and background classes, repsectively. When using LibSVM with the balanced dataset, equal weights were given to both classes. All numbers reported are from five-fold cross-validation. 
Features derived from natural language processing
Additional features were extracted from the abstract and full-text document collections using natural language processing. (This is in addition to the automatically extracted Gene Ontology annotations, which are also produced by natural language processing.) These features were word bigrams and collocations. Collocations, or sets of words that co-occur more often than expected, have not been commonly used in text classification, but provide a better reflection of the semantics of a text than bigrams. Both bigrams and collocations were extracted using the Natural Language Tool Kit (NLTK). 23 Any bigram or collocation where one of the tokens only contained punctuation was removed. Additionally, only those features that appear in three or more documents were retained. Six different NLP-derived feature sets were created by combining the three datasets (abstract, full-text, curated + abstract + full-text) along with the two different types of surface linguistic features (bigrams and collocations); these feature sets were tested and trained on both the balanced and unbalanced datasets.
Machine learning input
A breakdown of the kind and number of features used in each dataset can be seen in Table 2 .
Evaluation metrics
The performance of our classifier was assessed by estimating precision (P), recall (R), and Fmeasure (F). The area under the receiving operator characteristic curve (AROC) is reported, as it allows for comparison against other classifiers, but with a word of caution interpreting the unbalanced dataset: inflated AROCs have been seen when working with skewed class distributions. 24 All scores were determined by taking the average of 5-fold cross-validation for all datasets.
Results and Discussion
Enriched Gene Ontology concepts
To assess the viability of a machine learner separating background and pharmacogenes, we first determine whether functional differences between the pharamcogenes and background genes exist. At least one curated or text-mined functional annotation was retrieved for 23,647 out of 26,236 total genes (90% of all genes in PharmGKB). The details of obtaining the annotations are given in Sections 2.3 and 2.4. The gene sets and their annotations were passed to FatiGO, a web tool that extracts over-and under-represented GO concepts from two lists of genes, and a list of enriched GO concepts and probabilities was returned as output. Examining the output from FatiGO, we found that, depending on the dataset, between 800-4000 GO concepts were enriched, consistent with our hypothesis that there are enriched pharmacogenetic functions. The top 10 enriched GO concepts for Molecular Function and Biological Process can be seen in Tables 3 and 4 , respectively. These lists were obtained by comparing the annotations from all pharmacogenes to all background genes. To ensure that bias was not introduced solely because there is a large difference in the number of genes and the number of annotations between the two sets, another comparison was done between all pharamacogenes and the set of 1,124 background genes with equal representation in the biomedical literature. The enriched GO concepts returned are similar the concepts returned when comparing against all background genes, and therefore we can conclude that no bias is introduced. Because 800-4000 statistically enriched GO concepts were returned for each dataset, we can conclude that there are functional differences between the set of pharmacogenes and background genes. Many of the enriched GO concepts can be categorized as playing a role in pharmacodynamics (PD) or pharmacokinetics (PK). Pharmacodynamics is the study of the activity of a drug in the body, e.g. its binding and effect on the body. Examples of PD concepts are "integral to plasma membrane" (GO:0005887), "drug binding" (GO:0008144), and "positive regulation of protein phosphatase type 2B activity" (GO:0032514)-they are either associated with receptors that drugs bind to, or refer to the possible effect that a drug has on the body. Pharmacokinetics is the study of drug absorption, distribution, metabolism, and excretion. Examples of PK concepts are "xenobiotic metabolic process" (GO:0006805), "small molecule metabolic process" (GO:0044281), and "active transmembrane transporter activity" (GO:0022804)-they refer to metabolism of a molecule or are involved in the metabolism or transportation of a molecule. There are interesting differences when examining the top enriched concepts between the different datasets (curated, abstracts, and full text). Impressionistically, curated annotations seem to be more specific, while NLP annotations appear to be more general (especially evident when examining Biological Processes, Table  4 ). This may be the case because there are limitations to the depth in GO that concept recognizers can identify; a large gap exists between how nearterminal concepts are stated in the ontology and their expression in free text.
Classification of pharmacogenes
Having established that the functions of pharmacogenes are different from background genes, the next step is to test the ability of machine learning to differentiate between them. Our goal is to predict at genomewide scale pharmacogenes that are not currently known in PharmGKB to have drug or disease relationships. We approach the problem as binary classification, where the classifier separates pharmacogenes from the rest of the genes.
Classification using Gene Ontology concepts
To see how well known pharmacogenes can be classified through their functional annotation similarity, five classifiers were created using the manually curated and text-mined functional annotations on both the unbalanced and balanced datasets. Baselines for comparison against are a one-node decision tree (OneR), Naive Bayes, and randomly assigning class labels. Performance of all classifiers and baselines can be seen in Table 5 . A breakdown of features used for each dataset can be seen in Table 2 and a summary of functional annotations is seen in Table 1 . The results are shown in Table 5 . A clear effect of balance versus imbalance in the data is evident. Fmeasure increases between 0.29 and 0.53 when using a balanced training set. Examining performance across unbalanced training sets, we notice that Naive Bayes produces the highest recall (0.68) but the lowest precision (0.17), whereas Random Forest produces highest precision (0.69) but lowest recall (0.11). The same trends do not hold for the balanced training sets. On both training sets, it is the SVM-based classifiers that balance precision and recall and produce the highest Fmeasures. The highest Fmeasures of 0.81 and 0.78, are produced by LibSVM and SMO, respectively, on the balanced NLP abstract annotations. Naive Bayes and Random Forrest perform poorly in comparison to the SVM classifiers, but better than a single-node decision tree or random assignment; OneR performs slightly better than random assignment.
For a majority of the classifiers, GO annotations from literature produce the best performance-surprisingly, text-mined annotations seem to be better features than those from curated datasets. This could be explained by the difference in number of annotations, there are 15 times more text-mined annotations than curated ones (Table 1) . Another explanation could be that more information is encoded in text-mined annotations than just gene function. From this set of experiments, we can conclude that using only Gene Ontology concepts, we are able classify pharmacogenes on the balanced training set but it remains unclear, because of poor performance, whether it is sufficient to use only GO concepts with an unbalanced training set. We can also conclude that LibSVM should be used for the next set of experiments because it is best performing and was the fastest to train (training time not shown).
Classification using GO concepts and literature features
To test the hypothesis that features derived from surface linguistic features can increase performance over conceptual features alone, we trained classifiers with two additional feature types: bigrams and collocations. Bigrams consist of every sequence of two adjacent words in a document and are commonly used in text classification. Collocations are a subset of bigrams, containing words that co-occur more frequently than expected. They are a better representation of the semantics of a text than bigrams alone. The methods for extracting these features are described above in Section 2.7. Adding bigrams and collocations introduces up to 30x more features than functional annotations alone ( Table 2 ).
The performance of LibSVM with GO annotations and bigrams/collocations on both training sets can be seen in Table 6 . Baselines are the same. Table 5 . Classification using Gene Ontology concepts Five-fold cross validation performance of five binary classifiers when providing Gene Ontology concepts as features. Results from both unbalanced and balanced training sets are shown. The highest F-measure is bolded. The baselines provided are OneR (one-node decision tree), Naive Bayes, and randomly assigning classes (median of 5 random assignments). On the unbalanced training set, the maximum F-measure seen is 0.57, obtained by using text-mined functional annotations and bigrams extracted from abstracts. By using bigrams in addition to GO annotations, precision is increased by 0.17 while recall is decreased by 0.02, resulting in an increase in F-measure of 0.09 (Table 5  versus Table 6 ). On the balanced training set, the maximum F-measure seen is 0.81, also obtained by using textmined functional annotations and bigrams from abstracts. With the addition of bigrams, both precision and recall are increased by 0.06 and 0.03,respectively, resulting in an increase in Fmeasure of 0.06 (comparing Table 5 to Table 6 ).
Comparison with other methods
As mentioned in the introduction, there are very few methods against which our method can be compared. Most gene-disease or gene prioritization methods are designed to work on small sets of disease-specific genes, 12-14 while our method predicts pharmacogenes on a genome-wide scale. One method, Garten et al., 25 utilizes text mining to extract drug-gene relationships from the biomedical literature, also using PharmGKB as a gold standard, with an AUC of 0.701. The closest methods to ours do not predict pharmacogenes as defined here, but only predict disease genes. CIPHER 26 predicts human disease genes with precision of ∼0.10 using protein-protein interaction networks and gene-phenotype associations. PROSPECTR 27 uses Table 6 . Classification with GO concepts and natural language processing Five-fold cross-validation performance of LibSVM when combining Gene Ontology concepts and literature-based features. Both the balanced and unbalanced training results are shown. The highest F-measure and AROC are bolded. The baselines provided are OneR (one-node decision tree), Naive Bayes, and randomly assigning classes (median of 5 random assignments).
Abstract GO + Bigrams
Full-Text GO + Bigrams Combined GO + Bigrams Classifier P/R/F AUC P/R/F AUC P/R/F AUC While the majority of other methods utilize sequence-based features, protein interactions, and other genomic networks, our method requires only Gene Ontology annotations and simple bigrams/collocations extracted from biomedical literature. Precision and recall for our classifier trained on the unbalanced dataset with GO annotations and bigrams from abstracts are slightly lower than both PROSPECTR and the method presented in Costa et al., our AUC (0.771) is higher than all but the predicted druggable genes from Costa et al. Performance on the balanced training set using GO concepts and bigrams extracted from abstracts (F=0.86, AUC=0.860) are higher than any of the methods presented here.
Limitations
There are two major limitations of our work. The first is that we grouped together all pharmacogenes, while it may have been more useful to differentiate between disease-associated and drug-response-associated variant. The other limitation is that we don't provide a ranking, but rather just a binary classification.
Prediction of pharmacogenes
Now that classifiers have been created and evaluated, we can analyze the predicted pharmacogenes. 141 genes were predicted to be pharmacogenes by all six unbalanced datasets seen in Table 6 . Predictions from unbalanced models were analyzed because the models produced through balanced training were unknowingly weighted for recall. For example, the balanced model trained on abstract GO and bigrams produces a recall of 0.99 and precision of 0.10 when the classifier is applied to all genes in PharmGKB; this is not informative and further work and error analysis will be conducted to examine why this is. The top 10 predicted genes, ranked by functional similarity (as calculated by ToppGene) to the known pharmacogenes, along with all known information from PharmGKB and Online Mendelian Inheritance in Man (OMIM), 7 and if/what the gene was predicted to be by Costa et al. can be seen in Table 7 . We first notice that there are no gene-disease or genedrug relationships in PharmGKB for these predicted genes, but a few of them participate in curated pathways. We expand our search to see if other databases have drug or disease information about them. OMIM provides insight into genetic variation and phenotypes; half of the predicted genes have a variant that plays a role in a mutant phenotype. We also looked up our predicted genes in the results from a previous study on predicting morbid and druggable genes, and 90% (9 out of 10) of our predicted pharmacogenes were also predicted to be morbid (variations cause hereditary human diseases) or druggable. 18 To assess the hypothesized pharmacogenes further, PubMed and STITCH 28 were used to find any known drug or disease associations not in PharmGKB or OMIM. The top-ranked gene, GRIN2A, seems to play a part in schizophrenia and autism spectrum disorders 29 along with binding to memantine, a class of Alzheimer's medication blocking glutamate receptors. Interestingly, UGT1A is unable to be found in STITCH or OMIM, but an article from May 2013 introduces a specific polymorphism that suggests that it is an important determinant of acetaminophen glucuronidation and could affect an individual's risk for acetaminopheninduced liver injury. 30 It is also known to be linked to irinotecan toxicity. We also find genetic variations in GRIK1 have been linked to schizophrenia 31 and down syndrome. 32 Even only examining the top three predicted pharmacogenes, there is evidence in other databases and literature that suggests these should be further examined by the PharmGKB curators for possible annotation.
Conclusions
One of the surprising findings of this study was that features extracted from abstracts performed better than features extracted from full text. Since full text was available for a smaller number of genes, the comparison may not be appropriate. Pursuing this remains for further research.
The collocation features performed almost as well as the bigrams, despite the fact that we took a poor approach to extracting them, since we did collocation recognition on the document level, rather than on the level of the document collection as a whole. With a better approach to collocation extraction, performance of the collocation features might have been much higher.
The fact that features derived from text-mined functional annotations outperformed manually curated annotations was a surprise. In this work, we did not evaluate the correctness of text-mined functional annotations. Therefore, the performance of the text-mined functional annotation features is the only indication of how well the actual Gene Ontology concept recognition worked. Based on the fact that they performed higher than the manually curated Gene Ontology concepts, it appears that the performance of the ConceptMapper approach was at minimum good enough for this task.
In this paper we identified a set of functions enriched in known pharmacogenes. This list could be used to rank genes predicted by our classifier, but also has usefulness beyond the work presented here. The list could prove useful in literature-based discovery by providing linkages to identify gene-drug or gene-disease relationships from disparate literature sources.
We also present a classifier that is able to predict pharmacogenes at a genome wide scale (F=0.86, AUC=0.860). The top 10 hypothesized pharmacogenes predicted by our classifier are presented; 50% contain allelic variations in OMIM and 90% were previously predicted but remain unannotated in PhamGKB. Additionally, using other sources at least the top three genes predicted are known to bind a drug or to be associated with a disease. Other methods attempting similar problems, utilize sequence based features and genomic networks; only a few incorporate literature features. Our method, on the other hand, uses mainly features mined from the biomedical literature along with functional annotations from databases. Because our method offers comparable performance to others utilizing sequence and network based features, this work illustrates the importance of incorporating curated databases with information available in the biomedical literature for biomedical discovery.
